


PRODUCT INFORMATION



SB 265610

Item No. 17879

CAS Registry No.: 211096-49-0
Formal Name: N-(2-bromophenyl)-N'-(4-cyano-1H-benzotriazol-7-yl)-urea
MF: C₁₄H₉BrN₆O
FW: 357.2
Purity: ≥98%
UV/Vis.: λ_{max}: 282, 323 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SB 265610 is supplied as a crystalline solid. A stock solution may be made by dissolving the SB 265610 in the solvent of choice. SB 265610 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of SB 265610 in ethanol is approximately 5 mg/ml and approximately 3 mg/ml in DMSO and DMF.

SB 265610 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, SB 265610 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. SB 265610 has a solubility of approximately 0.16 mg/ml in a 1:5 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

CXCR2 (IL-8RB) is a seven-transmembrane G protein-coupled receptor whose physiological ligands include IL-8 (CXCL8) and many other CXC chemokines involved in the trafficking and activation of inflammatory cells. It is involved in various inflammatory diseases, including chronic obstructive pulmonary disease, psoriasis, rheumatoid arthritis, and ulcerative colitis. SB 265610 is a nonpeptide, allosteric, inverse agonist of CXCR2 (K_d = 2.51 nM) that prevents receptor activation by binding to a region distinct from the agonist binding site.^{1,2} It does not bind to the related CXCR1 receptor.¹ It has been shown to prevent neutrophil chemotaxis both *in vitro* and in a rat model of hyperoxia-induced lung injury.³

References

1. de Kruijf, P., van Heteren, J., Lim, H.D., *et al.* Nonpeptidergic allosteric antagonists differentially bind to the CXCR2 chemokine receptor. *J. Pharmacol. Exp. Ther.* **329**(2), 783-790 (2009).
2. Bradley, M.E., Bond, M.E., Manini, J., *et al.* SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor. *Brit. J. Pharmacol.* **158**, 328-338 (2009).
3. Auten, R.L., Richardson, R.M., White, J.R., *et al.* Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats. *J. Pharmacol. Exp. Ther.* **299**, 90-95 (2001).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/21/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM